Hepatocellular Carcinoma
Conditions
Brief summary
HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.
Detailed description
This will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.
Interventions
DIAGNOSTIC_TESTCT Imagesa in HCCT
Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter
Sponsors
Superior University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Both Male and Female. * Patients diagnosed with HCC who underwent TACE. * Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment. * Patients who underwent TACE within last your years from the study start date.
Exclusion criteria
* Patients with incomplete or missing medical records and imaging studies. * Patients with a history of severe comorbidities that might interfere with treatment response evaluation * Patients who were contraindicated for CT scans at the time of follow-up. * Patients that are contradicted with CT scan. * Patient who underwent TACE more than four years before the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| self admisistered questioner | 12 Months | self-administered questionnaire for the evaluation of HCCT, having a score range from 0 to 50. The more the score shows that issues worsen. |
Countries
Pakistan
Outcome results
None listed